We analyzed outcomes changes in the symptoms of dermatitis assessed by SCORAD, skin severity, and itch severity, changes in the quality of life reported at the end of therapy, and changes of cytokines (IFN-γ, Serum IgE, IL-4). This evidence concerns the gene IFNG and dermatitis.